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Summary
The high-cholesterol/high-fat Western diet has abetted an epidemic of atherosclerotic cardiovascular disease, the leading
cause of death in industrialized nations. Liver X receptors (LXRs) are oxysterol sensors that are required for normal
cholesterol and triglyceride homeostasis, yet synthetic LXR agonists produce undesirable hypertriglyceridemia. Here we
report a previously unrecognized role for hepatic LXR in the links between diet, serum lipids, and atherosclerosis. A
modest increase in hepatic LXR worsened serum lipid profiles in LDL-receptor null mice fed normal chow but had the
opposite effect on lipids and afforded strong protection against atherosclerosis on a Western diet. The beneficial effect
of hepatic LXR was abrogated by a synthetic LXR agonist, which activated SREBP-1c and its target genes. Thus, the
interplay between diet and hepatic LXR is a critical determinant of serum lipid profiles and cardiovascular risk, and
selective modulation of LXR target genes in liver can ameliorate hyperlipidemia and cardiovascular disease.Introduction
Atherosclerosis is the leading cause of death in industrialized
nations. One of the main causes of atherosclerosis is hyper-
cholesterolemia, which is a hallmark of the so-called “Western
lifestyle.” The marked dependence of cholesterol levels upon
lifestyle is illustrated by the rightward shift in the distribution of
plasma cholesterol levels for the entire population (Durrington,
2003). Indeed there is a linear relationship between the risk
factor cholesterol and protection from atherosclerosis (Levine
et al., 1995). Hypertriglyceridemia is also a major risk factor for
atherosclerosis (Assmann and Schulte, 1992). This has led to
intense efforts to lower cholesterol and triglycerides by a com-
bination of dietary and pharmacological interventions. In addi-
tion to diet, lipid profiles are regulated by multiple genes (Rader
et al., 2003). Interactions between genes and the nutritional
environment are increasingly recognized as critical for optimiz-
ing therapy (Ordovas and Corella, 2004).
Liver X receptors (LXRs) have emerged as key regulators of
cholesterol and lipid metabolism (Barish and Evans, 2004; Li
and Glass, 2004; Tontonoz and Mangelsdorf, 2003). LXRs are
members of the nuclear receptor (NR) family of lipid-sensing
transcription factors (Chawla et al., 2001). Like other NRs,
LXRs bind and recognize distinct subsets of target genes and
also bind lipophilic ligands that switch the receptors between
two states that either repress or activate transcription of these
genes (Glass and Rosenfeld, 2000; McKenna and O’Malley,
2002). Repression occurs in the absence of ligand, where the
LXR assumes a conformation that favors the binding of core-CELL METABOLISM : MAY 2005 · VOL. 1 · COPYRIGHT © 2005 ELSEVIEpressor molecules, N-CoR and SMRT, that inhibit transcription
of target genes (Hu and Lazar, 2000; Hu et al., 2003; Wagner
et al., 2003). Ligand binding shifts the LXR to an activated con-
formation that binds coactivators and stimulates transcription.
Physiological ligands for LXR are oxysterols derived from diet
and cholesterol metabolic pathways (Janowski et al., 1996).
There are two LXRs, α and β, which are about 77% homolo-
gous (Willy et al., 1995). LXRβ is ubiquitously expressed, whereas
LXRα is highly expressed in liver, intestine, adipose tissue, and
macrophages. Mice genetically lacking LXRα develop marked
hepatic steatosis and hypercholesterolemia when fed a choles-
terol- and fat-laden Western diet (Peet et al., 1998a). This phe-
notype appears to be related to LXR regulation of hepatic and
intestinal genes that maintain cholesterol homeostasis by con-
trolling intestinal absorption, reverse cholesterol transport, en-
dogenous cholesterol synthesis, and catabolism, as well as
excretion into the bile (reviewed in Millatt et al., 2003). Lack of
both LXR isoforms increases aortic foam cell formation as a
precursor for atherosclerosis (Schuster et al., 2002), whereas
potent pharmacological LXR agonists protect against athero-
sclerosis in apolipoprotein E (ApoE) or low-density lipoprotein
receptor (LDLR) null mice (Joseph et al., 2002; Terasaka et al.,
2003). The search for a mechanism by which LXRs protect
from atherosclerosis has focused on the macrophage because
transplantation of bone marrow from LXRα/β null mice ex-
acerbates atherogenesis in genetically susceptible mice (Tan-
girala et al., 2002). The protective effect of LXRs in the macro-
phage is likely a combination of their promotion of reverse
cholesterol transport and anti-inflammatory effects.R INC. DOI 10.1016/j.cmet.2005.04.005 297
A R T I C L EIn the liver, LXRs regulate lipid metabolism, but, although
chronic administration of pharmacological ligands reduces se-
rum cholesterol levels, they also lead to hepatic steatosis and
hypertriglyceridemia due to induction of fatty-acid synthesis,
limiting their utility (Schultz et al., 2000). These ligands are non-
selective, but specific LXR knockouts reveal that LXRα is
essential for the response to a dietary cholesterol overload
(Peet et al., 1998b). LXRβ null animals were unaffected when
challenged with a high-cholesterol diet but did show a de-
crease in serum triglycerides (Schuster et al., 2002). These data
suggest that LXRα is more important for cholesterol metabo-
lism and that LXRβ plays a role in triglyceride metabolism.
Here we have determined the effects of a modest increase
in the concentration of hepatic LXRα on lipid metabolism and
atherosclerosis susceptibility of LDLR null mice on chow and
high-fat diets. Increased hepatic LXRα worsened plasma cho-
lesterol and triglyceride concentrations on normal chow, but,
remarkably, when the same animals were fed a high-choles-
terol/high-fat Western-like diet, their serum lipid profile im-
proved and they were protected from atherosclerosis. The ben-
eficial effect of increased hepatic LXRα on serum lipids was
lost when the mice were treated with a pharmacological LXRα
agonist. Thus, increased hepatic expression of LXRα is benefi-
cial in a milieu of endogenous ligands generated from a West-
ern diet, but this is abrogated by treatment with a potent phar-
macological agonist. These findings demonstrate that hepatic
LXRα can be antiatherosclerotic in a diet- and ligand-depen-
dent manner.
Results
Generation of mice with liver-specific increase
in LXR expression
To determine the effect of increased hepatic LXRα on lipid me-
tabolism and atherosclerosis, the human LXRα cDNA was de-
livered to liver of LDLR null mice via adeno-associated virus
(AAV) gene transfer. The vector AAV2.8 has been previously
shown to enable highly reproducible, efficient, and selective
hepatic gene expression that is stable for at least 6 months
(Gao et al., 2002; Lebherz et al., 2004). Southern blot analysis
demonstrated that the hLXRα transgene was present in liver
but not in muscle-, fat-, or bone marrow-derived macrophages
of the treated animals (Figure S1). The hLXRα mRNA was ex-
pressed in liver but not in macrophages from AAV-LXRα-
treated mice (Figure 1A). Western blot analysis confirmed the
increase in hepatic LXRα protein concentration (Figure 1B).
Quantitative analysis revealed that the increase in hepatic
LXRα protein level was approximately 3-fold (Figure 1C).
Increased hepatic LXR worsens serum lipid profile
on a chow diet
On a low-fat/low-cholesterol diet of standard mouse chow,
male AAV-LXRα-treated mice had significantly higher serum
cholesterol and triglyceride levels than controls (Figures 2A and
2B). Fast performance liquid chromatography (FPLC) of serum
indicated that the main difference in cholesterol and triglycer-
ides was in the very low density lipoprotein (VLDL) subfraction,
which was significantly increased relative to control mice on
the same low-fat/low-cholesterol diet (Figures 2C and 2D). The
mechanism of this effect of hepatic LXRα was assessed by
measuring the expression of a number of LXR gene targets in298Figure 1. Mice with liver-specific increase in LXRα expression
Expression levels of human and mouse LXRα were determined in the liver of
AAV-GFP control and AAV-LXRα-treated animals. (A) Analysis of hLXRα gene
expression by reverse transcriptase-PCR in liver and macrophages and (B) total
LXRα protein levels in liver were measured by Western blot, using HDAC2 as
loading control; (C) densitometric quantification of LXR protein levels normalized
to HDAC2. *p < 0.05. Results are expressed as the mean ± standard error (SEM).liver (Figures 2E and 2F). Remarkably, the Cyp7a1 gene, which
is highly LXR responsive in rodents, was significantly repressed
by the increased hepatic LXRα, which would be expected to
contribute to the hypercholesterolemia. We further found a mild
but significant repression of ApoE, an LXR target gene that is
a major mediator in the uptake of triglyceride-rich lipoproteins
(Mak et al., 2002; Medh et al., 2000). Interestingly, PGC-1β was
induced nearly 2-fold in livers with elevated LXRα concentra-
tion (Figure 2E); a similar increase in hepatic PGC-1β has re-
cently been shown to contribute to hyperlipidemia (Lin et al.,
2005). Other LXR target genes were only minimally affected by
in the increase in hepatic LXRα (Figure 2F).
Increased hepatic LXR improves serum lipids in mice
on a Western diet
To assess the effects of increased hepatic LXRα on atheroscle-
rosis, male AAV-hLXRα mice were switched to a high-fat/high-
cholesterol Western diet that produces atherosclerotic lesions
in LDLR null mice (Ishibashi et al., 1993). Consistent with the
previous result, the AAV-LXRα mice had higher plasma choles-
terol and triglycerides prior to the dietary change. However, on
the Western diet the situation was reversed; in this nutritionalCELL METABOLISM : MAY 2005
Diet and hepatic LXR regulate CV metabolismFigure 2. Increased hepatic LXRα worsens serum
lipid profile on a chow diet
Serum cholesterol (A) and triglyceride (B) levels in
AAV-LXRα and AAV-GFP control LDLR null mice fed
on chow diets. Results are mean ± standard error
(SEM) of 8–10 animals per group. *p < 0.01. (C)
FPLC fractionation of cholesterol. (D) FPLC fraction-
ation of triglycerides. The location of the VLDL, LDL,
and HDL fractions are shown. (E) Gene expression
in liver of AAV-GFP and AAV-LXRα animals on chow
diet measured by Q-PCR. Results are normalized to
expression of 36B4, mean expression of GFP group
is normalized to 1. Results are expressed as the
mean ± standard error (SEM), five animals per group.
*p < 0.05.setting, a marked and sustained lowering of serum cholesterol
(Figure 3A) and triglycerides (Figure 3B) relative to control mice
was observed in mice with increased hepatic LXRα. FPLC
analysis of serum from the AAV-LXRα and AAV-GFP mice on
the Western diet demonstrated marked reductions in the VLDL
subfraction for both cholesterol (Figure 3C) and triglycerides
(Figure 3D). Serum LDL cholesterol was also significantly de-
creased in AAV-LXRα mice; although HDL cholesterol ap-
peared to be higher in the FPLC profile, this difference was not
statistically significant.
To determine the physiological basis for the decrease in se-
rum triglycerides in the AAV-hLXRα mice, we measured triglyc-CELL METABOLISM : MAY 2005eride secretion and VLDL turnover rates. There was no signifi-
cant difference in overall triglyceride secretion between the
AAV-hLXRα and the control group (Figure 3E). In contrast,
VLDL clearance was increased by about 30% (Figure 3F). The
percent increase in VLDL clearance was similar to that of the
reduction in circulating cholesterol and triglyceride levels, sug-
gesting that the increase in VLDL clearance is sufficient to ex-
plain the serum lipid phenotype of the AAV-LXRα mice. As ex-
pected, mice developed fatty liver on the high-fat Western diet
with histological evidence of disturbed architecture with in-
creased lipid accumulation, but there was no significant differ-
ence in either histology or liver triglyceride/cholesterol content299
A R T I C L EFigure 3. Hepatic LXRα improves lipid profile on
Western diet by increasing the clearance of VLDL
Male AAV-LXR and AAV-GFP control LDLR null mice
were fed chow diet then switched to Western diet.
Serum cholesterol (A) and triglyceride (B) were mea-
sured at the indicated times. *p < 0.05, **p < 0.01.
(C) FPLC fractionation of cholesterol. (D) FPLC frac-
tionation of triglycerides of pooled serum on West-
ern diet (n = 8–10/group). The location of the VLDL,
LDL, and HDL fractions are shown. (E) Triglyceride
secretion rate on Western diet (n = 7/group, p < 0.05
at baseline, p = n.s. at other time points). (F) VLDL
clearance on Western diet (n = 5/group, control nor-
malized to 1); *p < 0.05. Results are expressed as
the mean ± standard error (SEM).(Table S1 and Figure S2). There was also no difference in serum
transaminases between the AAV-hLXRα- and control AAV-
treated groups (data not shown).
Increased hepatic LXR regulates gene expression
differently on a Western diet
We explored the molecular basis of the metabolic effects of
increased hepatic hLXRα, focusing on critical enzymes and
transcription factors involved in cholesterol and triglyceride
metabolism. Improvement in cholesterol metabolism was likely
related to induction of Cyp7a1 and ABCG5 (Figure 4A), both of
which are established LXR target genes (Chiang et al., 2001;
Gupta et al., 2002; Repa et al., 2002). The marked induction of
Cyp7a1 on the Western diet contrasts with the repression due
to hepatic LXRα in mice fed the low-cholesterol/low-fat diet
(Figure 2E). This suggests that LXRα was activated on the300Western diet, perhaps by a diet-derived oxysterol ligand. Re-
pression of gene expression by LXRα is likely due to corepres-
sor recruitment in the absence of ligand (Hu et al., 2003;
Wagner et al., 2003). Consistent with previous reports of selec-
tive gene derepression in LXR null mice (Peet et al., 1998b;
Steffensen et al., 2004), not all genes induced by hepatic LXRα
on Western diet were repressed on normal chow.
Several genes that are likely related to the enhanced triglyc-
eride clearance were induced in the Western-diet-fed AAV-
LXRα mice (Figure 4B). ApoA5, a potent mediator of triglycer-
ide reduction via accelerated clearance of triglyceride-rich
VLDL (Baroukh et al., 2004; Merkel et al., 2005; Pennacchio et
al., 2001), was increased along with ApoA4, which might play
a synergistic role in enhancing the uptake of VLDL by increas-
ing LPL activity (Goldberg et al., 1990). ApoA4 has been shown
to be a direct LXR target gene (Liang et al., 2004). In addition,CELL METABOLISM : MAY 2005
Diet and hepatic LXR regulate CV metabolismFigure 4. Increased hepatic LXRα alters hepatic
gene expression and reduces atherosclerosis on a
Western diet
A and B) Expression was measured by Q-PCR, with
results normalized to expression of 36B4. Mean ex-
pression of GFP group is normalized to 1. Results
are expressed as the mean ± standard error (SEM)
of 8–10 animals per group. *p < 0.05, **p < 0.01,
***p < 0.001.
C) Total aortic plaque area (results of individual ani-
mals and mean are shown), with representative aor-
tae pictured.
D) Atherosclerotic burden at aortic root (results of
individual animals and mean are shown), with repre-
sentative sections shown. n = 12 male mice/group;
*p < 0.05, *p < 0.01 versus AAV-GFP.upregulation of carnitine palmitoyltransferase 1 (CPT1) in the
AAV-LXRα livers might promote triglyceride catabolism by
increasing oxidation of fatty acids (Foster, 2004). We also noted
an increased hepatic expression of SREBP-1 and PGC-1β in
the LXRα-treated animals, which would suggest an induction
of triglyceride synthesis. However, downstream SREBP-1
target genes such as fatty-acid synthase (FAS) and stearoyl-
CoA desaturase (SCD1) were not significantly changed (Fig-
ure 4B).
Increased hepatic LXR reduces atherosclerosis
on a Western diet
We next assessed the effect of increased hepatic LXRα on
atherosclerotic burden after 12 weeks on the Western diet (Fig-
ures 4C and 4D). En face analysis of total aortic plaque area
revealed that the mean atherosclerotic lesion area was reducedCELL METABOLISM : MAY 2005by w60% in AAV-hLXRα animals relative to control AAV-GFP
mice (Figure 4C). Independent measurement of plaque at the
aortic root also revealed marked protection from atherosclero-
sis in the AAV-LXRα mice (Figure 4D). Thus, consistent with
the pronounced improvement in serum lipid profiles, increased
hepatic LXRα levels protected LDLR null mice from develop-
ment of atherosclerosis on the Western diet.
We also compared the effects of increased hepatic LXRα in
male and female mice since beneficial effects of nuclear recep-
tor modulation on atherogenesis can be male specific (Li and
Glass, 2004). In this study, male and female LDLR null mice
were fed a Western diet 3 weeks prior to AAV-hLXRα treatment
to ensure severe pretreatment hypercholesterolemia, and the
Western diet was continued for an additional 12 weeks. In both
males and females, cholesterol and triglyceride levels were
markedly reduced soon after the increase in hepatic LXRα. The301
A R T I C L Eimprovement in lipid profiles was sustained and, if anything,
greater in females (Figures S3A–S3D). After 12 weeks, mice
were sacrificed and their atherosclerotic burden was evaluated.
In addition, total aortic plaque area decreasedw73% in males
and 46% in female AAV-LXRα animals relative to control (Fig-
ure S3E). Moreover, aortic root plaque size was significantly
decreased in both males and females (Figure S3F). Thus, in-
creased hepatic LXRα has beneficial effects upon lipid profile
and atherosclerosis in females as well as males.
Benefits of increased hepatic LXR are reversed
by a synthetic LXR agonist
We hypothesized that increased hepatic LXRα is beneficial for
serum lipids because of selective gene activation by the en-
dogenous ligands generated from the Western diet. However,
potent pharmacological LXRα ligands such as T0901317 ex-
acerbate hypertriglyceridemia (Grefhorst et al., 2002; Schultz
et al., 2000). To better understand the mechanisms involved,
we treated control and AAV-LXRα mice with T0901317 or vehi-
cle and measured serum lipid profiles in mice fed the high-fat/
high-cholesterol diet. As expected from earlier studies, AAV-
LXRα had reduced cholesterol (Figure 5A) and triglyceride (Fig-
ure 5B) levels. Remarkably, the triglyceride lowering was nearly
abolished by treatment with T0901317 (Figure 5B); the choles-
terol lowering was also partially reversed (Figure 5A). Clearly
there was a major difference between LXRα effects on he-
patic lipid metabolism in the context of endogenous ligands
versus potent pharmacological compounds. Physiologically,
T0901317 dramatically increased hepatic triglyceride secretionFigure 5. The synthetic LXR agonist T0901317 re-
verses the protective effect of hepatic LXRα on
lipid profile
AAV-GFP and AAV-LXR mice on Western diet were
treated with the synthetic LXR agonist T0901317
(T09) (n = 9/group). Serum cholesterol (A) and serum
triglycerides (B) are shown prior and post admin-
istration. (C) Triglyceride secretion of vehicle- or
T09-treated animals on Western diet (n = 5/group,
*p < 0.05, **p < 0.01). (D) VLDL clearance of vehicle-
or T09-treated animals on Western diet (n = 5/group,
control normalized to 1), *p < 0.01. T09 was admin-
istered for 3 days. Results are expressed as the
mean ± standard error (SEM).302(Figure 5C), with an additional inhibition of VLDL clearance
(Figure 5D).
To explore the molecular mechanisms underlying the oppo-
site effects of increased hepatic LXRα and synthetic LXRα
agonist, we utilized Affymetrix microarrays to assess the dif-
ferences in hepatic gene regulation among four groups: AAV-
GFP and AAV-LXRα mice fed Western diets, with or without
T0901317 treatment. Quite a few genes, many known to be
LXRα targets, were induced by T0901317 as well as by
AAV-LXRα with or without T0901317. These genes included
Cyp7a1, ABC transporters, and SREBP-1 (Figure 6A, top);
these changes were confirmed by quantitative PCR (Q-PCR)
(Figure 6B). Since these genes were regulated in the same di-
rection they were unlikely to explain the opposing effect of
T0901317 on lipid metabolism. Therefore, we focused on the
set of genes that were markedly induced by T0901317 in the
presence or absence of AAV-LXRα but were not induced by
AAV-LXRα alone (Figure 6A, bottom). Remarkably, this gene
set contained a panel of lipid metabolic regulators known to
be SREBP-1c target genes (Horton et al., 2003), including FAS
and SCD1. Differential induction of these and other SREBP-1
target genes in the T0901317-treated mice was confirmed by
Q-PCR analysis (Figure 6C).
SREBP-1 gene expression was induced in AAV-LXRα mice
as well as in animals treated with the synthetic LXR ligand.
However, SREBP-1 requires posttranslational cleavage to a
mature, nuclear localized form in order to activate gene expres-
sion. LXR agonists have been shown to enhance the post-
translational processing of SREBP-1c (DeBose-Boyd et al.,CELL METABOLISM : MAY 2005
Diet and hepatic LXR regulate CV metabolismFigure 6. SREBP-1 target genes are induced by
synthetic LXR ligand treatment but not by in-
creased LXRα
A) Profiling of liver RNA from AAV-GFP ± T09 or
AAV-LXRα ± T09 animals on Western diet. The en-
tire dataset is provided in the NCBI/Gene Expres-
sion Omnibus database. (A, top) Genes whose
mean upregulation was >1.6-fold for AAV-LXRα
and/or T09 ligand-treated. Listed in order of fold in-
duction: AAV-GFP/T09 versus AAV-GFP/vehicle. (A,
bottom) Genes whose mean upregulation was >1.6-
fold by T09 but not by AAV-LXRα in the absence of
synthetic ligand. Listed in order of fold induction:
AAV-GFP/T09 versus AAV-LXRα/vehicle.
B and C) Q-PCR analysis of hepatic gene expression.
Results are normalized to expression of β-actin, mean
expression of GFP/vehicle group is normalized to 1.
n = 4 mice per group. *p < 0.05, **p < 0.01, ***p <
0.001 compared to GFP/vehicle group. No signifi-
cant differences were found between AAV-GFP/T09
and AAV-LXRα/T09 group. Results are expressed as
mean ± standard error (SEM).2001), and we confirmed that T0901317 treatment increased
hepatic SREBP-1 maturation (Figure 7A). By contrast, in-
creased hepatic LXRα did not significantly alter the amount of
cleaved SREBP-1 in liver, even on the Western diet (Figure 7B).
Based on these findings, we hypothesized that the increase in
SREBP-1c target gene expression in AAV-LXRα mice treated
with the pharmacological ligand would be explained by an
increase in cleaved SREBP-1. Indeed, T0901317 treatment
markedly increased the active form of SREBP-1 in the livers of
AAV-LXRα mice (Figure 7C).
Discussion
We have found that increased hepatic LXRα expression pro-
tects against atherosclerosis in susceptible mice fed a Western
diet. Although LXR and its ligands are atheroprotective in theCELL METABOLISM : MAY 2005macrophage (Levin et al., 2005), our new findings demonstrate
that LXRα in the liver also has beneficial effects. The w3-fold
increase in LXRα in our model system was substantial but not
massive; changes of this magnitude are within the range of
genetic variations in gene expression due to promoter poly-
morphisms (Pastinen et al., 2004).
Remarkably, dietary fat and cholesterol strongly modified the
phenotype of mice with hepatic LXRα overexpression (Figure
7D). On a diet low in fat and cholesterol, hepatic LXRα actually
worsened serum lipid profiles. This was likely due in part to
increased hepatic expression of the coactivator PGC-1β, which
was recently shown to increase serum triglyceride levels (Lin
et al., 2005). The mechanism by which increased hepatic LXRα
induces PGC-1β remains to be determined. Another effect of
hepatic LXRα expression on the low-fat diet was repression
of the Cyp7a1 gene, which, by decreasing the conversion of303
A R T I C L EFigure 7. Synthetic LXR ligand but not increased
hepatic LXRα enhances maturation of SREBP in
liver
A) Western blot of mature SREBP-1 from liver of
vehicle- or T09-treated animals on Western diet;
RAN serves as loading control.
B) There was no difference in mature SREBP-1 in
liver of AAV-GFP- and AAV-LXR-treated animals on
Western diet.
C) T09 increases maturation of SREBP-1 in AAV-
GFP- and AAV-LXR-treated animals. HDAC2 serves
as loading control in (B) and (C).
D) Summary of the diet- and synthetic ligand-
dependent effects of hepatic LXR on lipid metabo-
lism. The major effects of Western diet and synthetic
LXR agonist on hepatic LXRα target genes and
SREBP-1c maturation are highlighted along with re-
sultant changes in serum lipid chemistries.cholesterol into bile acids, contributes to the increased serum
cholesterol (Spady et al., 1998). Cyp7a1 is a well-established
LXR target gene in rodents, and we hypothesize that, on the
chow diet, unliganded LXR repressed Cyp7a1 expression (Hu
et al., 2003; Wagner et al., 2003). Remarkably, the Cyp7a1
gene was induced by hepatic LXRα in mice fed a Western diet,
most likely due to an increase in endogenous oxysterol ligands.
Although we hypothesize a relative absence of endogenous
LXR ligand on the chow diet, it is also possible that there are
actually different ligands present or induced by the different
diets. In any case, repression was gene selective, which is con-
sistent with the pattern of gene derepression in LXR null mice
(Peet et al., 1998b; Steffensen et al., 2004) and reminiscent of
the target-gene-selective corepressor recruitment exhibited by
PPARγ in adipocytes (Guan et al., 2005).
On the Western diet, hepatic LXRα reduced serum lipid
levels largely by increasing their clearance. In addition to
upregulation of Cyp7a1, induction of the cholesterol transpor-
ter ABCG5 likely contributed to cholesterol lowering, while in-304duction of CPT1 would favor fatty acid oxidation and triglycer-
ide catabolism. Moreover, induction of ApoA5 has been shown
to improve triglyceride clearance (Merkel et al., 2005). Of note,
induction of ApoA5 was reversed by T0901317 (data not
shown), consistent with a recent report (Jakel et al., 2004). In-
duction of ApoA4 may also improve hypertiglyceridemia (Deeb
et al., 1996).
Many of the genes induced in the livers of AAV-LXRα mice
fed the Western diet are also induced by potent synthetic li-
gands. However, LXR ligands have been shown to induce hy-
pertriglyceridemia in several animal models (Chisholm et al.,
2003; Grefhorst et al., 2002; Joseph et al., 2002; Terasaka et
al., 2003). Remarkably, in our studies, treatment of the Western
diet-fed mice with T0901317 overturned the beneficial effects
of increased hepatic LXRα expression. This deleterious effect
of LXR agonism on lipid metabolism has been ascribed to in-
duction of the SREBP-1c gene (Repa et al., 2000). Indeed,
T0901317 increased TG secretion (Grefhorst et al., 2002) and
decreased VLDL clearance, which mimics the lipid phenotypeCELL METABOLISM : MAY 2005
Diet and hepatic LXR regulate CV metabolismof the SREBP-1 transgenic mouse on the LDLR null back-
ground (Horton et al., 1999). However, SREBP-1c gene expres-
sion was also increased in our AAV-LXRα mice. mRNA profiling
revealed that treatment of the AAV-LXRα mice with the potent
pharmacological ligand induced many SREBP-1c target genes,
whereas SREBP-1c induction in the setting of overexpressed
LXRα was insufficient to turn on downstream targets. This
correlated well with the increased generation of mature
SREBP-1 by T0901317 but not by the putative endogenous
LXR ligands generated by the Western diet. The increase in
activated SREBP in mice treated with the synthetic LXR ligand
is consistent with observations by the group of Brown and
Goldstein (DeBose-Boyd et al., 2001) and provides a plausible
mechanism to explain the reversal of the favorable lipid profile
of the AAV-LXRα mice by T0901317 (Figure 7D). The fact that
oxysterols (presumably the endogenous ligands produced by
the Western diet) potently suppress SREBP processing is likely
to contribute to this difference.
Overall, these results indicate that selective hepatic LXRα
overexpression is able to shift the fragile balance between tri-
glyceride synthesis, uptake, and metabolism to a more favor-
able phenotype in animals fed a Western diet. Remarkably, this
effect is diet dependent, and rather undesirable changes in
lipid metabolism occur in mice with the same genetic alteration
when fed a low-fat/low-cholesterol diet. This represents a vivid
example of a specific genetic alteration (increased hepatic
LXRα gene expression) with opposite phenotypic effects (im-
proved or worsened serum lipid profile) in different nutritional
environments (Western or low-fat diets). Thus, a polymorphism
in the LXRα promoter that increases hepatic expression might
reduce atherosclerotic risk in subsets of patients due to effects
of dietary factors that might vary even within a single family.
However, the benefit of increased hepatic LXRα is lost upon
treatment with a potent synthetic ligand due to activation of
the SREBP-1 pathway, demonstrating a fundamental differ-
ence between endogenous oxysterols and pharmacological
LXR agonists that are currently available. Therefore, selective
LXRα modulators that do not enhance posttranslational activa-
tion of SREBP-1 in liver have great potential as therapies for
lipid disorders and atherosclerosis.
Experimental procedures
Vectors
All constructs were expressed from a liver-specific expression cassette un-
der control of the thyroxine binding globulin promoter (Gao et al., 2002).
Transgenes were human LXRα (gift of David Moore) for the treatment group
and green fluorescent protein (eGFP) gene as control. To produce AAV vec-
tors encapsidated in an AAV8 capsid (AAV2.8), a pseudotyping strategy was
performed. Vectors were purified using a standard cesium sedimentation
method and titers were determined via TaqMan analysis using probes and
primers targeting the BGH poly(A+) region of the vectors (Gao et al., 2002).
Animal models
LDL-receptor null mice on C57BL/6 background were purchased from the
Jackson Laboratory (Bar Harbor, Maine) and maintained as a breeding col-
ony. Mice were given unrestricted access to water. Male mice were put on
normal chow for 12 weeks and switched to Western diet (0.15% cholesterol,
21% butterfat, DYETS, PA) thereafter. In another study, equal amounts of
male and female mice (n = 6 for each sex and treatment) were fed a high-
fat Western diet starting three weeks prior to vector injection to ensure
severe pretreatment hypercholesterolemia and kept on the diet for 12
weeks after vector injection. Blood was obtained at least two times before
and at designated time points after gene transfer. Vectors were injected viaCELL METABOLISM : MAY 2005tail vein or intraportal injection at a dose of 1 × 1012 genome copies/mouse.
For both studies, mice were randomly divided into two groups and injected
with either AAV2/8.TBG.LXRα (treatment group) or AAV2/8.TBG.eGFP (con-
trol group). At time of necropsy, the liver, epididymal fat, muscle, heart, and
aorta were harvested for further analysis. In addition, bone marrow-derived
macrophages were obtained by harvesting of bone marrow cells from femur
and tibia of mice. Cells were differentiated into macrophages for 7 days in
10% FBS in DMEM containing 10 ng/ml macrophage colony-stimulating
factor.
For triglyceride secretion and VLDL turnover studies using the pharmaco-
logical ligand, an age-matched cohort was put on a Western diet for 4
weeks. The LXR agonist T0901317 (Calbiochem/EMD Biosciences, San
Diego, California) was administered for 3 days (5 mg/kg, i.p.) before the
start of the respective experiment. All studies were approved by the Institu-
tional Animal Care and Use Committee of the Wistar Institute and the Uni-
versity of Pennsylvania.
Serum and liver lipid determination
Blood samples were obtained from the retroorbital plexus. For selected time
points, serum was pooled and lipoproteins were separated by fast perfor-
mance liquid chromatography (FPLC). The amount of plasma lipoproteins in
the serum or the FPLC fractions was detected using an automated clinical
chemistry analyzer (Schiapparelli Biosystems, Fairfield, New Jersey) or
manual assay (Wako, Richmond, Virginia). For quantification of liver choles-
terol and triglycerides, liver sections were homogenized and incubated in
chloroform/methanol (2:1) overnight. After addition of 0.05% H2SO4 and
centrifugation for 10 min, the lower layer of each sample was collected,
divided into two aliquots, and dried under nitrogen. For the cholesterol mea-
surement, the dried lipids of the first aliquot were dissolved in 1% Triton
X-100 in chloroform. Once dissolved, the solution was dried under nitrogen.
After dissolving the lipids in H20 and incubating for 30 min at 37°C, the total
cholesterol concentration was measured using a Total Cholesterol Kit (Wako
Diagnostics). For the second aliquot the dried lipids were dissolved in alco-
holic KOH and incubated at 60°C for 30 min. Then 1M MgCl2 was added,
followed by incubation on ice for 10 min and centrifugation at 14,000 rpm
for 30 min. The supernatant was finally evaluated for triglycerides (Wako Di-
agnostics).
Triglyceride synthesis
For determination of VLDL-TG production rates, mice were fasted for 4 hr
prior to the start of the kinetic study. 7.5% pluronic solution (poloxamer)
(Bass Lab, Mt. Olive, New Jersey) in sterile PBS was injected (400 l i.p.).
Blood was drawn from the retroorbital plexus before injection and 1 hr, 2
hr, 6 hr, and 24 hr after injection. Plasma triglyceride levels were assayed
and the secretion rate was calculated from the change in serum triglycer-
ides over time.
VLDL turnover
Mice were fasted overnight before the procedure. Each mouse was tail vein-
injected with 5,000,000 counts of [125I]-VLDL in 100 l sterile PBS. Blood
was drawn from the retroorbital plexus at 2 min, 20 min, 1 hr, 2 hr, 6 hr, and
24 hr after injection. Plasma was separated and ApoB-specific counts were
measured after isopropanol precipitation using a γ counter. Fractional cata-
bolic rate was calculated from the lipoprotein clearance data (Horton et
al., 1999).
Histological analysis
For the quantification of the aortic plaques, the mouse aorta was carefully
harvested after perfusion with ice-cold PBS, slit along the ventral midline
from the aortic arch down to the femoral arteries, and fixed in 10% phos-
phate-buffered formalin. The lipid-rich atherosclerotic plaques were stained
with Sudan IV (Sigma, St. Louis, Missouri) and the aorta pinned out flat on
a black wax surface. The image was captured with a Sony DXC-960 MD
color video camera. The area of both the plaque and the complete aortic
surface was determined using Phase 3 Imaging System (Media Cybernet-
ics, San Diego, California). Aortic valve plaque area was quantified from 10
m serial cryosections of the aortic root. All sections in which the aortic
valve was cut horizontally were stained with oil red O (Sigma). Three dif-
ferent sections per animal were evaluated. Plaque size was determined
using a Phase III imaging system. Histopathology of the liver and lipid accu-305
A R T I C L Emulation was evaluated in 10 m cryosections stained with oil red O and
counterstained with Mayer’s hematoxylin.
Immunoblot analysis
Liver sections were homogenized (RIPA Buffer plus proteinase inhibitors)
and protein isolated. Forty micrograms of reduced protein was resolved on
a 10% TrisGlycine gel and transferred to PVDF membrane. Antibodies used
were a polyclonal rabbit anti-human LXRα (Hu et al., 2003), polycolonal
rabbit anti-SREBP-1 (Santa Cruz Biotechnology, Santa Cruz, California),
polyclonal rabbit anti-HDAC2 (Santa Cruz Biotechnology), and monoclonal
anti-Ran (BD Biosciences) as internal control. Blots were developed using
chemiluminescence.
RNA isolation and quantification
RNA was isolated using RNeasy Mini Kit (Qiagen, Valencia, California), then
subjected to DNase digestion followed by reverse transcription (Invitrogen,
Carlsbad, California). mRNA transcripts were quantified by the dual-labeled
fluorogenic probe method for real-time PCR, using a Prism 7900 thermal
cycler and sequence detector (Perkin Elmer/ABI, Foster City, California).
The primers and probes used in the real-time PCR were the following:
Sense-Cyp7a1: 5#-CTGATCCGTCTACGCATGTTTC-3#, and
Antisense-Cyp7a1: 5#-CAGGAATGGTGTTTGCTTGAGA-3#,
Cyp7a1 Probe: 5#-FAM-CGCACCTTGTGATCCTCTGGGCA-TAMRA-3#.
Sense-ABCG5: 5#-GCGAGACGTTGCGATACACA-3#, and
Antisense-ABCG5: 5#-TGACTGCCTCTACCTTCTTGTTGT-3#,
ABCG5 Probe: 5#-FAM-TGCTGGCCCTCTGCCGCA-TAMRA-3#.
Sense 36B4: 5#-GGCACCGAGGCAACAGTT-3#, and
Antisense 36B4: 5#-TCATCCAGCAGGTGTTTGACA-3#,
36B4 Probe: 5#-FAM-AGAGCAGGCCCTGCACTCTCG-TAMRA-3#.
Sense-PGC-1β: 5#-CCCTGGCTGACATTCACTGAT-3#, and
Antisense-PGC-1β: 5#-CAGGTTGTGGGTCTCTGTATCCA-3#,
PGC-1β Probe: 5#-FAM-TAGGTGCTCTGCCCTCGATGTGCC-TAMRA-3#.
Sense-LPL: 5#-GCTTAAGTGGATGAGCGACTC-3#, and
Antisense-LPL: 5#-CAGATGAGAAACTTTCTCCCTAGCA-3#,
Probe LPL: 5#-FAM-CCCGACTGGTGGAGCAGCCC-TAMRA-3#.
Sense-ApoE: 5#-GAGAGCCGGAGGTGACAGATC-3#, and
Antisense-ApoE: 5#-CTCTTCCTGGACCTGGTCAGAA-3#,
ApoE Probe: 5#-FAM-CCGCCTCAAGGGCTGGTTCGA-TAMRA-3#.
Primers and probes for remaining genes were obtained from ABI. The
cycle number at which the transcripts of the gene of interest was detectable
(CT) was normalized to the cycle number of 36B4 detection, referred to as
delta CT. The fold change of the gene of interest expression relative to the
vehicle-treated group was expressed as 2−deltadeltaCT, in which deltadeltaCT
equals the deltaCT of the compound treated group minus deltaCT of the
chosen control group, which was normalized to 1.
RNA profiling
Microarray analysis was performed by the University of Pennsylvania Micro-
array facility. All protocols were conducted as described in the Affymetrix
GeneChip Expression Analysis Technical Manual (Santa Clara, California).
Briefly, 5 g of total RNA was converted to first-strand cDNA using Super-
script II reverse transcriptase primed by a poly(T) oligomer that incorporated
the T7 promoter. Second-strand cDNA synthesis was followed by in vitro
transcription for linear amplification of each transcript and incorporation of
biotinylated CTP and UTP. The cRNA products were fragmented to 200
nucleotides or less, heated at 99°C for 5 min, and hybridized for 16 hr at
45°C to Affymetrix MOE 430 A microarrays. The microarrays were then
washed at low (6× SSPE) and high (100 mM MES, 0.1M NaCl) stringency
and stained with streptavidin-phycoerythrin. Fluorescence was amplified by
adding biotinylated anti-streptavidin and an additional aliquot of streptavi-
din-phycoerythrin stain. A confocal scanner was used to collect fluores-
cence signal at 3 m resolution after excitation at 570 nm. The average
signal from two sequential scans was calculated for each microarray fea-
ture. Data were analyzed using Gene Spring software (Silicon Genetics,
Redwood City, California) with GC RMA File processing. Annotations were
made using Stanford Source.306Supplemental data
Supplemental data include three figures, one table, and dataset and can be
found with this article online at http://www.cellmetabolism.org/cgi/content/
full/1/5/297/DC1/.
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